Pearce IP BioBlast™: w/e 26 Jun 2020

by | Jun 29, 2020

Significant biosimilar activities this week include

June 20 | The NZ Herald reported a new study by NZ scientists which indicates that transgenic goats are capable of producing milk with high levels of cetuximab.

22 Jun 20 | Ankylosing Spondylitis News reported new data from Germany indicates Simponi® (golimumab) is an effective therapy for people with ankylosing spondylitis and other chronic inflammatory conditions, regardless of pre-treatment with other TNF inhibitors.

25 Jun 20 | Sandoz launched its ‘Biosimilars Generation’ campaign, aimed to help Canadians better understand the benefits of biosimilars, their safety and efficacy, and the opportunities for cost savings.  The campaign includes a new website aimed at supporting and educating Canadians.

25 Jun 20 | Aptevo Therapeutics announced it will receive quarterly “low single digit” fixed royalty payments from Pfizer (Wyeth) for 7 years from the first launch of Ruxience® (biosimilar rituximab).  The original royalty agreement was signed by Trubion Pharmaceuticals which was then acquired by Aptevo’s spin-off Emergent BioSolutions, and Wyeth, in 2016.  The royalty is applied to net sales in the US, EU and Japan.

26 Jun 20 | Samsung Bioepis announced the CHMP has adopted a positive opinion for Aybintio® (biosimilar bevacizumab).

26 Jun 20 | Janssen announced it has discontinued its Ph III LOTUS study of Stelara® (ustekinumab) in Systematic Lupus Erythematosus due to lack of efficacy.

27 Jun 20 | Shanghai Henlius Biotech announced the Investigational New Drug application for HLX14 (biosimilar denosumab) has been approved by China’s NMPA for the treatment of postmenopausal osteoporosis.

Print Page Mail Article

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News